It’s only fair to share… ABBV 744 N-Ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl]-6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 1H-Pyrrolo[2,3-c]pyridine-2-carboxamide, N-ethyl-4-[2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl]-6,7-dihydro-6-methyl-7-oxo- Molecular Weight 491.55 Formula C₂₈H₃₀FN₃O₄ CAS No. 2138861-99-9 ABBV-744 is a highly BDII-selective BET bromodomain inhibitor, used in the research of inflammatory diseases, cancer, and AIDS. Acute Myeloid Leukemia (AML) Phase I, AbbVie is evaluating oral agent ABBV-744 in early clinical trials for the treatment of metastatic castration …
Tag «PHASE 1»
CC-90010
It’s only fair to share… CC-90010 C21 H21 N O4 S, 383.46 CAS 1706738-98-8 1(2H)-Isoquinolinone, 4-[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-2-methyl- 4-[2-(Cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-2-methyl-1(2H)-isoquinolinone 4-[2-(Cyclopropylmethoxy)-5-(methanesulfonyl)phenyl]-2-methylisoquinolin-1(2H)-one 4-[2-(Cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Quanticel Pharmaceuticals Inc, Michael John BennettJuan Manuel BetancortAmogh BoloorStephen W. KaldorJeffrey Alan StaffordJames Marvin Veal Celgene (now a wholly owned subsidiary of Bristol-Myers Squibb ) , following its acquisition of Quanticel , is developing CC-90010, an oral inhibitor of BET (bromodomain and extraterminal) …
IIIM-290
It’s only fair to share… IIIM-290 4H-1-Benzopyran-4-one, 2-[2-(2,6-dichlorophenyl)ethenyl]-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]- Molecular Weight 462.32 Formula C₂₃H₂₁Cl₂NO₅ CAS No. 2213468-64-3 CSIR-IIIM Jammu has filed an IND Application of “IIIM-290” to Drug Controller General of India for conducting Phase I/Phase II clinical trial of its capsule formulation in patients with locally advanced or metastatic pancreatic cancer. This IND candidate …
J-147
It’s only fair to share… J-147 N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N’-[(E)-(3-methoxyphenyl)methylene]acetohydrazide Molecular FormulaC18H17F3N2O2 Average mass350.335 Da 2,2,2-trifluoroacetic acid-1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide Acetic acid, 2,2,2-trifluoro-, 1-(2,4-dimethylphenyl)-2-[(1E)-(3-methoxyphenyl)methylene]hydrazide N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N’-[(E)-(3-methoxyphenyl)methylene]acetohydrazide [1146963-51-0] 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide, 2,2,2-trifluoro-acetic acid 1146963-51-0 [RN] DOUBLE BOND GEOMETRY UNSPECIFIED 1807913-16-1 [RN] AS PER https://chem.nlm.nih.gov/chemidplus/sid/1807913161 E FORM FDA UNII Z41H3C5BT9 Abrexa Pharmaceuticals, Dementia, Alzheimer’s type, PHASE1 Blanchette Rockefeller Neurosci Inst (Originator) Salk Institute for Biological Studies (Originator) Abrexa Pharmaceuticals is …
AK-3280
It’s only fair to share… AK-3280 AK 3280; GDC3280; RG 6069 C19 H15 F3 N4 O2, 388.34 CAS 1799412-33-1 4H-Benzimidazol-4-one, 1,5-dihydro-1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-5-[4-(trifluoromethoxy)phenyl]- Ci8Hi4N502F3, mass 389.3 g/mol), ROCHE, Ark Biosciences , under license from Roche , is developing AK-3280, an antifibrotic agent, for the potential oral treatment of IPF. In July 2018, Ark intended to further clinical development of the drug, for IPF. …
SY-008
It’s only fair to share… SY-008 CAS 1878218-66-6 FREE FORM 1480443-32-0 SGLT1 inhibitor (type 2 diabetes), β-D-Glucopyranoside, 4-[[4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)-1-buten-1-yl]-2-methylphenyl]methyl]-5-(1-methylethyl)-1H-pyrazol-3-yl, acetate (1:1) acetic acid;(2S,3R,4S,5S,6R)-2-[[4-[[4-[(E)-4-(2,9-diazaspiro[5.5]undecan-2-yl)but-1-enyl]-2-methylphenyl]methyl]-5-propan-2-yl-1H-pyrazol-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol 4-{4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1H-pyrazol-3-yl beta-D-glucopyranoside acetate MF H50 N4 O6 . C2 H4 O2 MW 58.8 g/mol,C35H54N4O8 Originator Eli Lilly Developer Eli Lilly; Yabao Pharmaceutical Group Class Antihyperglycaemics; Small molecules Mechanism of Action Sodium-glucose transporter 1 inhibitors Phase I Diabetes mellitus 28 Aug 2018 No recent reports of …
Picropodophyllin
It’s only fair to share… Picropodophyllin Picropodophyllotoxin CAS 477-47-4 AXL1717, NSC 36407, BRN 0099161 414.4 g/mol, C22H22O8 (5R,5aR,8aS,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Furo(3′,4′:6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R-(5-alpha,5a-alpha,8a-alpha,9-alpha))- 5-19-10-00665 (Beilstein Handbook Reference) Axelar is developing picropodophyllin, a small-molecule IGF-1 receptor antagonist for the treatment of cancer including NSCLC and malignant astrocytoma. In February 2019, a phase Ia study was planned to initiate for solid tumor …
HEC-68498
It’s only fair to share… HEC-68498, CT-365 CAS 1621718-37-3 C20 H13 F2 N5 O3 S 441.41 Benzenesulfonamide, N-[5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluoro- N-[5-(3-Cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxy-3-pyridinyl]-2,4-difluorobenzenesulfonamide HEC Pharm , Calitor Sciences Llc; Sunshine Lake Pharma Co Ltd PHASE 1, idiopathic pulmonary fibrosis and solid tumors Phosphoinositide 3-kinase inhibitor; mTOR inhibitor Originator HEC Pharm Developer HEC Pharm; Sunshine Lake Pharma Class Anti-inflammatories; Antifibrotics; Isoenzymes Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors …
GNE-0877
It’s only fair to share… GNE-0877 Maybe DNL-151 ? CAS 1374828-69-9 Chemical Formula: C14H16F3N7 Molecular Weight: 339.31895 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile Denali Therapeutics Inc, useful for treating Alzheimer’s disease, breast tumor, type I diabetes mellitus and Crohn’s disease GNE-0877 is a highly potent and selective LRRK2 inhibitor. Leucine-rich repeat kinase 2 (LRRK2) has drawn significant interest in the neuroscience …
BIIB-095
It’s only fair to share… BIIB-095 ROTATION (+) 1493790-64-9 CAS free form, 1493772-48-7 cas Hcl salt cas 1493790-65-0, 1496563-32-6 ,SULPHATE ??? cas 1496563-31-5 SULFATE 1;1 cas 1496563-32-6 SULFATE HYDRATE 1;1;1 (2R,5S)-7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1 ,7-diazaspiro[4.4]nonan-6-one 1,7-Diazaspiro[4.4]nonan-6-one, 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]-, (2R,5S)- C20 H21 F3 N4 O, 390.40 Originator Biogen Class Analgesics Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors Phase I Neuropathic pain 29 Mar 2018 Phase-I clinical trials in Neuropathic pain (In volunteers) in …